Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer

[21] Cowan D(2011)Androgen receptor expression and breast cancer survival in postmenopausal women Clin Cancer Res 17 1867-3616

[22] Conway K(2009)Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients Clin Cancer Res 15 3610-1769

[23] Karaca G(2011)Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial Br J Cancer 104 1762-243

[24] Troester MA(2014)The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping Breast 23 234-2767

[25] Tse CK(2011)Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies J Clin Invest 121 2750-68

[26] Edmiston S(2012)Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity J Clin Pathol 65 64-590

[27] Deming SL(2010)Expression and clinical significance of androgen receptor in triple negative breast cancer Chinese J Cancer 29 585-5329

[28] Geradts J(2012)Effects of bicalutamide and 4OH-tamoxifen on androgen-regulated gene expression in the LNCaP cell line Anticancer Res 32 5323-2509

[29] Cheang MC(1981)Androgen-induced remissions after antiestrogen and hypophysectomy in stage IV breast cancer Cancer 48 2507-367

[30] Nielsen TO(2013)Androgen Receptor-Positive Triple Negative Breast Cancer: A Unique Breast Cancer Subtype Ann Surg Oncol 21 361-644

[21] Cowan D(2011)Androgen receptor expression and breast cancer survival in postmenopausal women Clin Cancer Res 17 1867-3616

[22] Conway K(2009)Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients Clin Cancer Res 15 3610-1769

[23] Karaca G(2011)Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial Br J Cancer 104 1762-243

[24] Troester MA(2014)The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping Breast 23 234-2767

[25] Tse CK(2011)Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies J Clin Invest 121 2750-68

[26] Edmiston S(2012)Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity J Clin Pathol 65 64-590

[27] Deming SL(2010)Expression and clinical significance of androgen receptor in triple negative breast cancer Chinese J Cancer 29 585-5329

[28] Geradts J(2012)Effects of bicalutamide and 4OH-tamoxifen on androgen-regulated gene expression in the LNCaP cell line Anticancer Res 32 5323-2509

[29] Cheang MC(1981)Androgen-induced remissions after antiestrogen and hypophysectomy in stage IV breast cancer Cancer 48 2507-367

[30] Nielsen TO(2013)Androgen Receptor-Positive Triple Negative Breast Cancer: A Unique Breast Cancer Subtype Ann Surg Oncol 21 361-644